List of Xeljanz drug patents
Xeljanz is owned by Pf Prism Cv.
Xeljanz contains Tofacitinib Citrate.
Xeljanz has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Xeljanz are:
- US6965027
Xeljanz was authorised for market use on 06 November, 2012.
Xeljanz is available in tablet;oral dosage forms.
The generics of Xeljanz are possible to be released after 08 December, 2025.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6965027 | PF PRISM CV | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(2 days ago) | |
| USRE41783 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(2 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 14, 2024 |
| New Patient Population (NPP) | Sep 25, 2023 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Market Authorisation Date: 06 November, 2012
Treatment: NA
Dosage: TABLET;ORAL
XELJANZ family patents
3
United States
1
South Africa
1
Denmark
1
IB
1
Austria
1
Mexico
1
Australia
1
Hong Kong
1
Russia
1
Uruguay
1
Norway
1
Germany
1
Argentina
1
Colombia
1
Brazil
1
Honduras
1
Guatemala
1
Cyprus
1
Spain
1
Peru
1
Korea, Republic of
1
Poland
1
Taiwan, Province of China
1
China
1
Japan
1
Canada
1
Panama
1
New Zealand
1
European Union
Xeljanz is owned by Pfizer.
Xeljanz contains Tofacitinib Citrate.
Xeljanz has a total of 1 drug patent out of which 0 drug patents have expired.
Xeljanz was authorised for market use on 25 September, 2020.
Xeljanz is available in solution;oral dosage forms.
The generics of Xeljanz are possible to be released after 08 December, 2025.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(2 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Sep 25, 2023 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Market Authorisation Date: 25 September, 2020
Treatment: NA
Dosage: SOLUTION;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic